Table 3 Baseline disease characteristics of the per protocol population
Mean (SD) | Placebo (n = 7) | Namilumab 150 mg (n = 7) | Namilumab 300 mg (n = 7) | Total (N = 21) |
|---|---|---|---|---|
DAS28-ESR | 4.7 (0.33) | 4.9 (0.35) | 4.4 (0.59) | 4.7 (0.47) |
DAS28-CRP | 4.0 (0.35) | 4.4 (0.33) | 4.0 (0.62) | 4.1 (0.46) |
ESR, mm/hour | 31.3 (7.43) | 27.7 (5.94) | 23.0 (8.06) | 27.3 (7.66) |
CRP, mg/liter | 16.4 (25.09) | 9.1 (6.42) | 11.5 (10.44) | 12.2 (14.91) |
TJC (0–68) | 6.6 (2.15) | 10.0 (6.98) | 9.6 (4.69) | 8.7 (5.00) |
SJC (0–66) | 3.4 (1.4) | 4.7 (2.14) | 6.1 (5.3) | 4.8 (3.42) |
PGA for pain | 54.6 (14.9) | 58.4 (21.1) | 50.1 (16.7) | 54.3 (17.5) |
PGA of DAS | 42.4 (21.1) | 59.9 (19.3) | 43.3 (16.4) | 39.5 (18.9) |